An individually assessed risk profile is pivotal in guiding the optimal duration of DAPT after PCI with latest-generation DES.
Risk stratification via scores may optimize DAPT duration post-PCI; extends evidence for individualized decisions but requires prospective validation.
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) using the latest-generation drug-eluting stents remains a matter of debate. Evidence suggests short regimens of DAPT are favorable for patients with a low ischemic risk, while those at a high risk of ischemia may benefit from taking DAPT for a long duration. An individually assessed risk profile is pivotal in guiding DAPT duration. Risk scores may aid individual patient DAPT decisions, but the value they add to clinical outcomes still needs to be established in a prospective randomized trial. This review aims to provide an overview on DAPT, evaluate the available evidence on DAPT duration with a description of common pitfalls of trial interpretation, and assess available tools for individual risk assessment in patients scheduled for PCI with the latest-generation DES.
No takes yet. Share an insight, caveat, or question.
Rik Rozemeijer (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: